1. Scrip
  2. >>Focus On Asia

Kanebo Recalls Rhododenol-Based Skin Brighteners From Asian Markets

 
• By Ryan Nelson

As many as 450,000 units under an array of brands are being recalled by Kao Corporation’s Kanebo Cosmetics unit following reports suggesting that the company’s Rhododenol brightening ingredient can leave white blotches on skin.

[Kao Corp.]’s Kanebo Ltd. Cosmetics unit is recalling from Japan, Hong Kong and other Asian markets an array of products designed to brighten skin with its Rhododenol ingredient, which has been linked to reports of consumers developing white blotches on their skin.

The voluntary action, which covers more than 50 SKUs in total, concerns 4-(4-hydroxyphenyl)-2-butanol, a substance derived from the bark of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer

 
• By Andy Smith

The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.